Iovance Biotherapeutics, Inc. IOVA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.43M-17.7% | $86.77M+28.6% | $67.46M+12.5% | $59.95M+21.5% | $49.32M-33.1% | ||
| $42.5M-1.4% | $43.11M+12.0% | $38.48M-32.1% | $56.66M+32.7% | $42.72M+13.0% | ||
| $28.93M-33.7% | $43.66M+50.7% | $28.98M+781% | $3.29M-50.2% | $6.61M-81.6% | ||
| 40.5%-9.8pp | 50.3%+7.4pp | 43%+37.5pp | 5.5%-7.9pp | 13.4%-35.3pp | ||
| $62.49M-12.2% | $71.2M-5.3% | $75.17M-5.3% | $79.36M+4.5% | $75.97M+7.0% | ||
| $38.95M+7.0% | $36.4M+5.3% | $34.56M-8.3% | $37.7M-13.9% | $43.8M+3.5% | ||
| $11.27M— | —— | $11.9M— | —— | $22.92M— | ||
| $8.54M-10.3% | $9.52M+5.7% | $9.01M-3.7% | $9.35M+15.9% | $8.07M-11.9% | ||
| $152.47M-4.8% | $160.23M-1.3% | $162.36M-6.5% | $173.73M+1.9% | $170.55M+6.4% | ||
| -$81.04M-10.3% | -$73.46M+22.6% | -$94.9M+16.6% | -$113.77M+6.1% | -$121.22M-40.0% | ||
| -113.5%-28.8pp | -84.7%+56.0pp | -140.7%+49.1pp | -189.8%+56.0pp | -245.8%-128pp | ||
| $1.33M-23.4% | $1.74M+40.0% | $1.24M-69.7% | $4.1M+27.5% | $3.22M-66.4% | ||
| -$79.71M-11.1% | -$71.72M+23.4% | -$93.66M+14.6% | -$109.67M+7.1% | -$118M-53.2% | ||
| -$665K— | $0+100% | -$2.41M-221% | $1.99M+208% | -$1.84M— | ||
| -$79.05M-9.9% | -$71.9M+21.2% | -$91.25M+18.3% | -$111.66M+3.9% | -$116.16M-47.9% | ||
| -110.7%-27.8pp | -82.9%+52.4pp | -135.3%+51.0pp | -186.2%+49.3pp | -235.5%-129pp | ||
| -$0.19— | —— | —— | -$0.33+8.3% | -$0.36-44.0% | ||
| -$0.19-26.7% | -$0.15+40.0% | -$0.25+24.2% | -$0.33+8.3% | -$0.36-44.0% | ||
| 418.5M+17.1% | 357.3M— | —— | 334.5M+3.6% | 322.9M+11.4% | ||
| 418.5M+17.1% | 357.3M-1.8% | 364M+8.8% | 334.5M+3.6% | 322.9M+11.4% | ||
| $1.02M-22.2% | $1.31M-7.0% | $1.41M-34.5% | $2.15M-11.2% | $2.42M-24.2% | ||
| $5.12M-9.8% | $5.67M+13.2% | $5.01M-21.2% | $6.36M-35.9% | $9.92M-26.2% | ||
| $5.13M+6.1% | $4.84M-11.8% | $5.48M-14.8% | $6.44M-39.2% | $10.58M-26.2% | ||
| $71.43M-17.7% | $86.77M+28.6% | $67.46M+12.5% | $59.95M+21.5% | $49.32M-33.1% | ||
| $11.27M-4.6% | $11.82M-0.7% | $11.9M-20.4% | $14.94M-34.8% | $22.92M-26.0% | ||
| —— | $15.39M0.0% | $15.39M0.0% | $15.39M0.0% | $15.39M-43.8% | ||
| -$81.04M-10.3% | -$73.46M+22.6% | -$94.9M+16.6% | -$113.77M+6.1% | -$121.22M-40.0% | ||
| -$78.22M-12.2% | -$69.74M+24.1% | -$91.92M+16.7% | -$110.37M+7.0% | -$118.65M-42.4% | ||
| -$78.22M-12.2% | -$69.74M+24.1% | -$91.92M+16.7% | -$110.37M+7.0% | -$118.65M-42.4% | ||
| -109.5%-29.1pp | -80.4%+55.9pp | -136.3%+47.8pp | -184.1%+56.5pp | -240.6%-128pp | ||
| -$81.04M-10.3% | -$73.46M+22.6% | -$94.9M+16.6% | -$113.77M+6.1% | -$121.22M-40.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Gross margin is 36.7% and operating margin is -127.2%, with a -123.9% net margin.
- Where does Iovance Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.